HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shuji Ohta Selected Research

Rheumatoid Arthritis

4/2015Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.
9/2014Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs.
3/2014Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.
1/2014Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).
1/2014Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
1/2014Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study.
11/2012Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.
11/2012Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.
1/2006Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shuji Ohta Research Topics

Disease

9Rheumatoid Arthritis
04/2015 - 01/2006
2Lung Diseases (Lung Disease)
11/2012 - 11/2012
2Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia)
11/2012 - 11/2012
2Opportunistic Infections (Opportunistic Infection)
11/2012 - 11/2012
2Dermatomyositis (Dermatopolymyositis)
06/2004 - 08/2002
1Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
02/2015
1Hypersensitivity (Allergy)
03/2014
1Acute Disease
01/2014
1Hypoxia (Hypoxemia)
01/2006
1Autoimmune Diseases (Autoimmune Disease)
12/2004
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
06/2004
1Neurogenic Diabetes Insipidus (Central Diabetes Insipidus)
06/2004
1Polymyositis
08/2002

Drug/Important Bio-Agent (IBA)

4tocilizumab (atlizumab)FDA Link
03/2014 - 01/2014
3Biological ProductsIBA
04/2015 - 03/2014
3Methotrexate (Mexate)FDA LinkGeneric
09/2014 - 11/2012
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2012 - 08/2002
2Abatacept (Orencia)FDA Link
04/2015 - 09/2014
2Antirheumatic Agents (DMARD)IBA
09/2014 - 03/2014
2AntibodiesIBA
03/2014 - 06/2004
2Etanercept (Enbrel)FDA Link
11/2012 - 11/2012
1p38 Mitogen-Activated Protein KinasesIBA
02/2015
1IsoxazolesIBA
02/2015
1Biomarkers (Surrogate Marker)IBA
01/2014
1Interleukin-6 (Interleukin 6)IBA
01/2014
1polyglucosanIBA
01/2006
1Vasopressins (Vasopressin)IBA
06/2004
1CytokinesIBA
08/2002
1Interleukin-15 (Interleukin 15)IBA
08/2002

Therapy/Procedure

3Therapeutics
11/2012 - 12/2004
1Subcutaneous Injections
01/2014
1Retreatment
01/2014
1Artificial Respiration (Mechanical Ventilation)
01/2006